Discovery of Phthalazine Derivatives as New PARP1 Inhibitors Through 3D-QSAR, Molecular Docking, and MD Studies
Iranian Journal of Pharmaceutical Research · 16.06.2026 · 25 (1)
DOI: 10.5812/ijpr-169970 ↗Kurz gefasst
Fachartikel in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 16.06.2026. Verfasst von Tahereh Sedghamiz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shiraz University of Medical Sciences, Shiraz, Iran. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Poly(ADP-ribose) polymerase 1 (PARP1) is a well-established therapeutic target in cancer owing to its critical role in DNA damage repair. In this study, we combined structure-based and ligand-based computational approaches to identify and optimize phthalazine derivatives as new PARP1 inhibitors.
Objectives
This study aimed to highlight the potential of computationally guided drug discovery in developing novel phthalazine-based PARP1 inhibitors and to support their candidacy as anticancer agents.
Methods
A 3D-QSAR model was generated using Phase and demonstrated strong statistical performance (R2 = 0.89, Q2 = 0.701). ADME/T predictions further confirmed the drug-like properties of the optimized compounds. A set of intrinsic PARP1 inhibitors was docked using Glide XP, and detailed interaction analyses were performed. To further validate the docking results, molecular dynamics (MD) simulations were conducted on the top three compounds.
Results
Contour map analysis indicated that steric, electrostatic, hydrogen-bond donor/acceptor, and hydrophobic fields play important roles in determining biological activity. Favorable and unfavorable regions near functional groups such as carbonyls, amines, and aromatic rings provided guidance for designing more potent derivatives. Several newly designed phthalazine derivatives showed improved docking scores and formed more stabilizing interactions than reference inhibitors such as fluzoparib. Among them, compounds 42 and 63 displayed the strongest binding affinities and robust interaction profiles, including multiple conserved hydrogen bonds and π–π stacking interactions. The MD trajectories demonstrated stable binding within the PARP1 active site, with persistent hydrogen bonds, particularly those with Ser904 and Gly863, supporting the reliability of the docking and QSAR findings.
Conclusions
The integrated QSAR, docking, and MD approaches provide strong evidence for the potential of phthalazine derivatives as novel PARP1 inhibitors and identify promising candidates for further experimental validation in anticancer drug discovery.
Autor:innen und Institutionen
- Shiraz University of Medical Sciences, Shiraz, Iran.
- University of Turin, Turin, Italy.
Zitieren
APA
Sedghamiz, T., Asgharpour Hasan Kiyadeh, S., Moosavi, F., & Poustforoosh, A. (2026). Discovery of Phthalazine Derivatives as New PARP1 Inhibitors Through 3D-QSAR, Molecular Docking, and MD Studies. Iranian Journal of Pharmaceutical Research, 25(1). https://doi.org/10.5812/ijpr-169970
Vancouver
Sedghamiz T, Asgharpour Hasan Kiyadeh S, Moosavi F, Poustforoosh A. Discovery of Phthalazine Derivatives as New PARP1 Inhibitors Through 3D-QSAR, Molecular Docking, and MD Studies. Iranian Journal of Pharmaceutical Research. 2026;25(1). doi:10.5812/ijpr-169970
BibTeX
@article{Sedghamiz2026,
author = {Sedghamiz, Tahereh and Asgharpour Hasan Kiyadeh, Somayeh and Moosavi, Fatemeh and Poustforoosh, Alireza},
title = {Discovery of Phthalazine Derivatives as New PARP1 Inhibitors Through 3D-QSAR, Molecular Docking, and MD Studies},
journal = {Iranian Journal of Pharmaceutical Research},
year = {2026},
volume = {25},
number = {1},
doi = {10.5812/ijpr-169970}
}
EUVIMED